Going Nuclear with Amino Acids and Proteins: Basic Biochemistry and Molecular Biology Primer for the Technologist

Krystle Glasgow[1], Mike Dillard[2], Eric Hertenstein[3], Allen Justin[4], Remo George[1], and Amy Brady[1]

[1]Nuclear Medicine and Molecular Imaging Sciences Program, Department of Clinical and Diagnostic Sciences, School of Health Professions, University of Alabama at Birmingham, Birmingham, Alabama; [2]Department of Nuclear Medicine, PET/CT, and Therapeutics, Inland Imaging, LLC, Spokane, Washington; [3]Nuclear Medicine Institute and Master of Science in Radiologic Sciences Graduate Program, Diagnostic Services Department, University of Findlay, Findlay, Ohio; and [4]Western Sierra Collegiate Academy, Rocklin, California

In recent years, there has been an influx of new tracers into the field of nuclear medicine and molecular imaging. Most of those that have been Food and Drug Administration–approved for clinical imaging exploit various mechanisms of protein biochemistry and molecular biology to bring about their actions, such as amino acid metabolism, protein folding, receptor–ligand interactions, and surface transport mechanisms. In this review, we attempt to paint a clear picture of the basic biochemistry and molecular biology of protein structure, translation, transcription, posttranslational modifications, and protein targeting, in the context of the various radiopharmaceuticals currently used clinically, all in an easy-to-understand language for entry-level technologists in the field. Tracer characteristics, including indications, dosage, injection-to-imaging time, and the logic behind the normal and pathophysiologic biodistribution of these newer molecular tracers, are also discussed.

Key Words: proteins, biochemistry, molecular biology, molecular imaging, molecular therapy

Proteins are the fundamental building blocks of every cell (*1*). They are made up of specific sequences of amino acids joined by peptide bonds and are arranged end to end in long chains called polypeptides. Two amino acids joined by a peptide bond is called a dipeptide, 3 amino acids linked by a peptide is a tripeptide, and so on, with an 8-amino-

acid sequence making up an octapeptide as seen with the radiotracer ^{111}In-octreotide (*2*). The sequence of amino acids in proteins is determined by the genetic code of the DNA. The gene sequence in the DNA is transcribed into the messenger RNA (mRNA) in the nucleus by an enzyme called RNA polymerase, with the help of a host of assisting enzymes called transcription factors. The initial mRNA contains sequences that code for the protein (exon) along with noncoding regions (introns), which are processed (spliced) to obtain the final mRNA with the correct sequence coding for the given protein. One gene may code for multiple proteins, whereby the same gene sequence is spliced out in a variety of different patterns to yield function proteins of differing sequences (alternative splicing). This process increases the diversity and the coding capacity of the genes. However, aberrant splicing reactions can result in disease conditions such as β-thalassemia, which is a severe blood disorder characterized by abnormal formation of hemoglobin (*3*).

Once spliced, the processed mRNA is then exported from the nucleus into the cytoplasm. On reaching the cytoplasm, the ribosomes (protein-producing molecular machines) hop onto the mRNA in search of a specific 3-nucleotide sequence called the start codon, which will act as a cue for the ribosome to start building the polypeptide chain on the basis of the subsequent nucleotide sequences. In eukaryotes (organisms with an intact nucleus, which includes everything from amoebas, worms, birds, and plants to humans), the start codon usually codes for the amino acid methionine (*4*). In prokaryotes (unicellular organisms without a nucleus, in which the DNA is floating in the cytoplasm, including members such as bacteria and archaea), it is a modified version of methionine (formyl methionine) (*5*). The nucleotide sequence in the mRNA is read in triplets (codon), and each

codon codes for an amino acid. However, one amino acid may be called on by different codons with differing nucleotide sequences (degeneracy of the codon), and this property of the genetic code makes it more fault-tolerant for point mutations. As the ribosomes move down the mRNA, reading the codons, the amino acids are brought to the ribosomes by specific transfer RNAs that carry the corresponding amino acid and have matching anticodon nucleotide sequences that can correctly base-pair (form a covalent bond) to the codon on which the ribosome sits at any given moment. The new amino acid is then added to the methionine (or to formyl methionine) in a condensation reaction in which a molecule of water is removed to form a peptide bond (-CONH-) between the terminal carbon atom of the methionine (C-terminal) and the amino terminal of the next amino acid (N-terminal) (Fig. 1) (6).

The previous transfer RNA (which brought in the methionine) is released, and the ribosome along with the new transfer RNA now carrying the 2 amino acids (dipeptide) then proceeds to the next codon. The process is repeated to generate a tripeptide, tetrapeptide, pentapeptide, and so on, until a long polypeptide protein chain is created as prescribed by the genetic code. Once the ribosome reaches the stop codon with a sequence that does not code for an amino acid and no transfer RNAs are recruited, the ribosomes recruit a release factor enzyme that causes hydrolysis of the final C-terminal group of the polypeptide and attaches it to the ribosome, thus resulting in release of the full-length polypeptide chain. There are multiple ribosomes hurtling down the mRNA doing the translation simultaneously, one behind the other, resulting in many polypeptides being synthesized from an mRNA and thereby increasing the yield of the protein product manyfold. Once the protein chain is translated, it must then be folded in precise 3-dimensional conformations for it to become functionally active. This folding process is done cotranslationally by special molecular chaperone proteins

that guide the nascent polypeptide chain to fold into its secondary, tertiary, and quaternary structures (7). The precise folding of the long polypeptide chain is important for correct forming of the protein's active site where the catalyzing reaction occurs or for stable incorporation of the necessary ion or chemical group (cofactor) to achieve its designated biologic task (8). The secondary structure of the protein is formed by the meticulous folding of the peptide chain into a helix or a pleated sheet. This process is mediated by the specific φ- and ψ-torsion angles of the amino acids that would result in hydrogen bonding of the adjacent groups of the amino acids in the vicinity. The order of the amino acids specified by the genetic code dictates this folding process, which would result in an energetically favorable (less entropy) stable conformation (Fig. 2) (9).

The chain of helices and sheets is further folded in 3-dimensional space and stabilized by hydrogen bonds and ionic interactions between atoms within the chain and within the watery (aqueous) environment in the cytoplasm (Fig. 3).

Once the chain is correctly folded into its tertiary structure, it may then need to join cooperatively with one or more folded peptide chains to form the final functional quaternary structure (e.g., hemoglobin is made up of 4 folded polypeptide subunits with an iron group stabilized in the middle of each subunit) (Fig. 4) (10,11). Similarly, an antibody protein, such as the one used in the non-Hodgkin lymphoma radioimmunotherapy agent ^{90}Y-ibritumomab tiuxetan, is made up of 4 different polypeptide chains (primary structure) that are folded into β-barrels (secondary structures). This folding in turn makes it possible for those from the same and adjacent chains to form bonds with each other called disulfide bridges (tertiary structure), thus giving the antibody molecule its final 3-dimensional Y shape (quaternary structure) (12).

If the protein is not correctly folded, it may be destroyed by specialized enzymes called proteasomes (13). In some pathologic situations, this misfolding of proteins may result in aberrant protein aggregates such as those seen in Alzheimer disease, where the proteins amyloid β and tau are incorrectly folded, resulting in sticky tarlike plaques in the neuronal tissue of the brain and further leading to inflammation and associated pathology (14). These misfolded protein aggregates in the affected neurons of the brain are the

FIGURE 1. Condensation reaction. Two amino acids are joined together to form peptide bond with release of water molecule.


FIGURE 2. Protein secondary structure formation. Precise folding of polypeptide chain is achieved by rotational angles (φ, ψ) of backbone bonds flanking central α-carbon atom of each amino acid. These rotational angles are specific for each amino acid and are instrumental in shaping protein structure as prescribed by genetic code.

FIGURE 3. Protein tertiary structure: intra- and intermolecular bonds help form and stabilize precise 3-dimensional protein structure into helices and sheets.

targets of the Alzheimer detection agents ^{18}F-florbetaben, ^{18}F-florbetapir, and ^{18}F-flutemetamol, all of which detect amyloid β-plaques (15), and ^{18}F-flortaucipir, which detects misfolded tau protein tangles (Fig. 5) (16).

Once the protein is correctly folded, it either stays in the cytoplasm or is exported outside the cell to its correct destination in the body. This process is guided by the types of amino acid residues, called signal sequences, in the N-terminal region of the polypeptide chain (e.g., hormones such as insulin are produced by the pancreas and are secreted into the blood for blood sugar regulation, whereas digestive enzymes are secreted by stomach cells into the gut for the task of digestion) (17).

Some proteins are shunted to the cell surface to be part of the cell membrane to act as switches (also known as receptors) for transmitting a signal into the cell's nucleus. The signal starts a specific cellular function based on environmental cues or based on another specific outside protein, such as a hormone or neurotransmitter, binding to it (18). These receptors have extremely specialized functions, such as when cluster-of-differentiation (CD) receptor protein CD20 (detected by the tracer ^{90}Y-ibritumomab tiuxetan) on the surface of B lymphocytes helps to produce antibodies (19), or when the CD206 protein (bound by the lymphoscintigraphy mannose sugar tracer ^{99m}Tc-tilmanocept) on the surface of macrophages scavenges sugar molecules from pathogens (20). Sometimes a receptor is synthesized in many almost-identical forms (also known as subtypes) to achieve a variety of functions in different organs by the same activator ligand, as is the case with several subtypes of somatostatin receptor (SSTR): SSTR1, SSTR2 (bound by the neuroendocrine tumor theranostic agents ^{68}Ga/^{177}Lu/^{64}Cu-DOTATATE, ^{68}Ga/^{177}Lu/^{64}Cu-DOTATOC, and ^{111}In-octreotide), SSTR3 (bound by ^{111}In-octreotide), SSTR4, and SSTR5 (bound by ^{68}Ga/^{177}Lu/^{64}Cu-DOTATATE, ^{68}Ga/^{177}Lu/^{64}Cu-DOTATOC, and ^{111}In-octreotide), all of which, in response to somatostatin, inhibit a variety of cell growth and other activities from their cell surface locations depending on the organ (or cancer) in which they are present (21). Such versatile protein receptors are sometimes localized to the cytoplasm itself, such as the estrogen receptors (bound by the breast carcinoma estrogenlike synthetic tracer ^{18}F-fluoroestradiol), which would need the activating estradiol molecule (serving as a ligand) to cross the cell membrane and bind to the receptors. This causes the receptors to physically move into the nucleus and start the transcription of a multitude of genes regulating many important body functions, such as cell proliferation and bone health (22).

Not all surface proteins take up the role of being receptors for cell-signaling activities. Some function as carriers of other molecules across the cell membrane, such as when the dopamine active transporter helps to transport (reuptake) the secreted excitatory neurotransmitter dopamine back into the neuron (23). Also taken up into intact neurons in the brain is the Parkinson disease tracer ^{123}I-ioflupane, which is analogous to dopamine (24). Similarly, the uptake-1 transporter helps the reuptake of the neurotransmitter norepinephrine back into the neuron. This reaction also occurs with the neuroendocrine tumor theranostic agent [123/131]I-*meta*-iodobenzylguanidine (MIBG), which is analogous to norepinephrine (25,26).


FIGURE 4. Protein quaternary structure: helices and pleated sheets of different polypeptide chains may further associate together to form quaternary structures as in case of hemoglobin molecule in red blood cells. Each hemoglobin molecule is composed of 4 polypeptide subunits (2 α-chains and 2 β-chains), each stabilized by ion group (heme) in center.

FIGURE 5. Protein misfolding can lead to pathology. Correct folding of protein into its proper 3-dimensional structure is important to function correctly. Incorrectly folded proteins either are destroyed by proteasomes or may form insoluble aggregates such as plaques, tangles, and Lewy bodies, which can lead to pathologic conditions as in Alzheimer disease.

Cell surface protein transporters act as transporters of not only neurotransmitters but also a variety of other biomolecules, including amino acids, which are needed for protein synthesis. In humans, there are 10 different types of amino acid transporters. Some of these, including L-type amino acid transporter and alanine-serine-cysteine transporter 2, in increased numbers are seen transporting large amounts of amino acids, such as leucine, into the cells for increased protein synthesis due to high demand in a cancerous state (27). A similar reaction occurs with the artificial nonmetabolizable amino acid leucin analog tracer ^{18}F-fluciclovine for prostate cancer imaging (28).

Some proteins, on the other hand, act as enzyme catalysts. A protein enzyme catalyzes a reaction by creating a conducive and protective environment in its active site that will produce an ideal condition for the chemical reaction to proceed (decrease of activation energy for starting the chemical reaction, resulting in the product's becoming more stable than the reactants) (Fig. 6) (29). These principles govern all the chemical reactions that take place in our body for the reactions to work in a complex chemical environment. An example of a cell surface transport protein that also acts as an enzyme is the prostate-specific membrane antigen (PSMA) seen on normal prostate cells, as well as on some other organs, including the kidneys, small intestine, and nervous system. PSMA enzymatically acts on dietary folic acid (vitamin B9) and on the neurotransmitter N-acetylaspartylglutamic acid to releases the amino acid glutamate, which helps mobilize calcium to support normal cell growth in the prostate and maintain neuronal functions in the brain (30,31). The increased presence of PSMA on prostate cancer cells is the target for the imaging agents ^{68}Ga-PSMA11 and ^{18}F-piflufolastat, which were approved by the Food and Drug Administration in 2020 and 2021, respectively.

MOLECULAR TRACER USING AMINO ACID METABOLISM (^{18}F-FLUCICLOVINE (AXUMIN; BLUE EARTH DIAGNOSTICS) (32))

[18]F-fluciclovine is a synthetic amino acid that resembles leucine and is labeled with the radionuclide [18]F. It was approved by the Food and Drug Administration in 2016 for imaging of prostate cancer recurrence with increased blood levels of prostate-specific antigen. ^{18}F-fluciclovine is carried across the cancer cell's membrane by the L-type amino acid transporter and by alanine-serine-cysteine transporter 2, which are seen in higher amounts in cancer cells. The driving force for this tracer uptake, apart from the increased need of the cancer cells for amino acids for protein building, are the androgens (male sex hormone produced in the testicles), which in general are dangerous proponents of cancer growth. In one type of treatment for prostate cancer, biochemical castration, drugs are given that shut down production of this hormone in the male gonads. However, nature may eventually bypass this effect in some patients by producing androgen from sources outside the testicles or through DNA-changing mutations, eventually resulting in recurrence of prostate cancer and metastasis. This condition is clinically called metastatic castration-resistant prostate cancer. ^{18}F-fluciclovine, once transported into the prostate cancer cells, gets trapped in the cells. Being an artificial amino acid, it cannot be used for protein building by the cell's transfer RNAs and ribosomes (Table 1).

MOLECULAR TRACERS DETECTING PROTEIN FOLDING OR MISFOLDING

[18]F-Florbetapir (Amyvid; Lilly), ^{18}F-Florbetaben (Neuraceq; Life Molecular Imaging), and ^{18}F-Flutemetamol (Vizamyl; GE Healthcare) (33–35)

[18]F-florbetapir, ^{18}F-florbetaben, and ^{18}F-flutemetamol bind to the misfolded β-amyloid proteins forming plaques in the brain of Alzheimer disease patients, specifically plaques that appear in the gray matter of the outer cerebral cortex, where β-protein should not be present (Table 2).


FIGURE 6. Enzyme as catalysts. Enzymes catalyze chemical reactions by lowering activation energy required for reactants to progress through steps of chemical reaction. This lowering of energy includes that of the high-energy transition state at the peak of the energy profile, which is lower when enzymes are present, hence making it easier for reaction to progress.

TABLE 1
Clinical Properties of Current Food and Drug Administration–Approved Molecular Tracer ([18F]-Fluciclovine) Using Amino Acid Metabolism

Property	Description
Indication	Imaging in men with suspected prostate cancer recurrence based on elevated blood level of prostate-specific antigen after treatment
Administered dose for adults	370 MBq (10 mCi)
Injection route	Intravenous
Injection-to-imaging time	4–10 min
Normal biodistribution	Pancreas, liver, bone marrow, muscle

[18F]-Flortaucipir (Tauvid; Lilly) (36)

[18F]-flortaucipir binds to misfolded tau protein clumps called neurofibrillary tangles in the brain of Alzheimer disease patients (Table 2).

MOLECULAR TRACERS TARGETING CELL SURFACE PROTEIN RECEPTORS

[18F]-Fluoroestradiol (Cerianna; Zionexa) (37)

[18F]-fluoroestradiol is indicated for use in PET imaging for the detection of estrogen receptor–positive lesions in patients with recurrent or metastatic breast cancer. [18F]-fluoroestradiol is a synthetic estrogen analog that migrates to the estrogen receptor proteins in the cytoplasm of breast cancer cells (Table 3).

[99mTc]-Tilmanocept (Lymphoseek; Cardinal Health) (38)

[99mTc]-tilmanocept is indicated for use with or without scintigraphic imaging for lymphatic mapping using a handheld γ-probe to locate lymph nodes draining a primary solid-tumor site as a component of intraoperative management. It is also indicated with or without scintigraphic imaging for guiding a sentinel lymph node biopsy using a handheld γ-probe in patients with clinically node-negative squamous cell carcinoma of the oral cavity or with breast cancer or melanoma. [99mTc]-tilmanocept is made up of many units of diethylenetriamine pentaacetic acid (kidney-imaging agent) and mannose (a type of sugar), linked together on a carbohydrate dextran backbone to form a giant molecule that is able to bind to the CD20 receptor protein on the surface of macrophages (a type of disease-fighting blood cell constantly

TABLE 2
Clinical Properties of Current Food and Drug Administration–Approved Molecular Tracers Detecting Protein Folding or Misfolding

Property	Description
Indication	
[18F]-florbetapir	Imaging β-amyloid plaques in suspected AD patients
[18F]-florbetaben	Imaging β-amyloid plaques in suspected AD patients
[18F]-flutemetamol	Imaging β-amyloid plaques in suspected AD patients
[18F]-flortaucipir	Imaging aggregated tau neurofibrillary tangles in suspected AD patients
Administered dose for adults	
[18F]-florbetapir	370 MBq (10 mCi)
[18F]-florbetaben	296 MBq (8 mCi)
[18F]-flutemetamol	185 MBq (5 mCi)
[18F]-flortaucipir	370 MBq (10 mCi)
Injection route	Intravenous
Injection-to-imaging time	
[18F]-florbetapir	30–50 min
[18F]-florbetaben	45–130 min
[18F]-flutemetamol	80–100 min
[18F]-flortaucipir	80–100 min
Normal biodistribution	
[18F]-florbetapir	Inner white matter, from which blood clearance is slower
[18F]-florbetaben	Inner white matter, from which blood clearance is slower
[18F]-flutemetamol	Inner white matter, from which blood clearance is slower
[18F]-flortaucipir	Some normal retention in choroid plexus, striatum, and brain stem nuclei

AD = Alzheimer disease.

TABLE 3
Clinical Properties of Current Food and Drug Administration–Approved Molecular Tracers Targeting Cell Surface Protein Receptors

Property	^{18}F-fluoroestradiol	^{99m}Tc-tilmanocept	^{68}Ga-DOTATATE, ^{68}Ga-DOTATOC, ^{177}Lu-DOTATATE, ^{64}Cu-DOTATATE, and ^{111}In-pentetreotide	^{90}Y-ibritumomab tiuxetan
Indication	Detecting estrogen receptor–positive lesions as adjunct to biopsy in patients with recurrent or metastatic breast cancer	Mapping lymph nodes draining from primary tumor site and guiding sentinel lymph node biopsy with intraoperative γ-probe	^{68}Ga-DOTATATE or ^{68}Ga-DOTATOC: locating SSTR-positive neuroendocrine tumors in adult and pediatric patients; ^{177}Lu/^{64}Cu-DOTATATE: treating SSTR-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults*	Evaluating relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma
Administered dose for adults	111–222 MBq (3–6 mCi)	18.5 MBq (0.5 mCi)	^{68}Ga-DOTATATE: 2 MBq/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi); ^{68}Ga-DOTATOC: adult—148 MBq (4 mCi); pediatric—1.59 MBq/kg (0.043 mCi/kg) with range of 11.1 MBq (0.3 mCi) to 111 MBq (3 mCi); ^{177}Lu-DOTATATE: 7.4 GBq (200 mCi) every 8 wk for total of 4 doses; ^{64}Cu-DOTATATE: 148 MBq (4 mCi); ^{111}In-pentetreotide: 111–222 MBq (3–6 mCi)	14.8 MBq per kg (0.4 mCi/kg); dose adjustment needed if platelet counts are low
Injection route	Intravenous	Subcutaneous, intradermal, subareolar, or peritumoral injection in 1 mL or less	Intravenous	Intravenous
Injection-to-imaging time	80 min	10–15 min	^{68}Ga-DOTATATE: 40–90 min; ^{68}Ga-DOTATOC: 60 min†	Imaging not usually done
Normal biodistribution	Hepatobiliary system (excretion); intestines (excretion); heart, blood, uterus, kidney (excretion); and bladder (excretion)	Lymphatic channels draining injection site	Pituitary, thyroid, spleen, adrenals, kidney, pancreas, prostate, liver, and salivary glands	Significant marrow and splenic distribution without cold antibody pretreatment; pretreatment with rituximab cold anti-CD20 antibody blocks CD20 sites of normal circulating B-cells in spleen and bone marrow by binding to it, thereby allowing the following hot antibodies to reach tumor areas

*^{111}In-pentetreotide: detection of neuroendocrine tumors bearing somatostatin receptors.
†^{177}Lu-DOTATATE: not imaged; ^{64}Cu-DOTATATE: not imaged; ^{111}In-pentetreotide: 24–48 h.

patrolling the blood and lymph nodes). When injected under the skin, ^{99m}Tc-tilmanocept drains into the lymph and accumulates in the macrophages in the sentinel lymph node and beyond (Table 3).

^{68}Ga/^{177}Lu/^{64}Cu-DOTATATE (NETSPOT [Advanced Accelerator Applications]/LUTATHERA [Advanced Accelerator Applications]/Detectnet [Curium]), ^{68}Ga/^{177}Lu/^{64}Cu-DOTATOC, ^{68}Ga/^{177}Lu/^{64}Cu-DOTANOC, and ^{111}In-Octreotide (OctreoScan; Curium) (39–42)

The molecular agents ^{68}Ga/^{177}Lu/^{64}Cu-DOTATATE, ^{68}Ga/^{177}Lu/^{64}Cu-DOTATOC, ^{68}Ga/^{177}Lu/^{64}Cu-DOTANOC, and ^{111}In-octreotide bind to protein receptors on the surface of SSTR-containing neuroendocrine tumors. This binding is selective for the subtype of SSTR, with radiolabeled DOTATATE and DOTATOC binding to SSTR2 and SSTR5 whereas ^{111}In-octreotide binds to all 3 SSTR subtypes (SSTR2, SSTR3, and SSTR5). The radiolabeled DOTATATE fits the classic definition of a theranostic radiopharmaceutical, in that the same agent can be used for both diagnostic (^{68}Ga-DOTATATE) and therapeutic (^{177}Lu/^{64}Cu-DOTATATE) purposes (Table 3).

^{90}Y-Ibritumomab Tiuxetan (Zevalin; Acrotech Biopharma) (43)

The antibody radiopharmaceutical ^{90}Y-ibritumomab tiuxetan binds to CD20 receptor protein molecules on mature and malignant B lymphocytes, a type of disease-fighting cell in the blood, while sparing the immature and parent cells in the bone marrow. Although the function of the CD20 receptor on B cells is unknown, it is thought to play a role in calcium entry across the B-cell membrane and in maintenance of the required amounts of calcium inside the cell for activation in the disease-fighting process, including antibody production. The big advantage of anti-CD20 antibodies is that they attack only malignant B cells and not the precursor cells, thus preventing the patient from losing all B cells, avoiding even more negative outcomes. The β-radiation from the ^{90}Y isotope then destroys the cancerous B cells (Table 3).

MOLECULAR IMAGING TRACERS TARGETING CELL SURFACE PROTEIN TRANSPORTERS

^{123}I-Ioflupane (DaTscan; GE Healthcare) (44)

^{123}I-ioflupane binds to presynaptic dopamine transporters, seen in the striatal region of the brain. A defining feature of Parkinson disease is a marked reduction in the dopamine-secreting neurons in this portion of the brain. Dopamine, once secreted into the synaptic gap between the presynaptic and postsynaptic neurons (neurons sending and receiving the nerve signals, respectively), is reabsorbed back into the presynaptic neuron through the dopamine transporter proteins on the presynaptic neuron endings, thus preventing continuous excitation. The nerve signals are related to higher-order functions of the brain, including movement and coordination. In the absence or destruction of these neurons, movement disorders typical to those of Parkinson syndromes will

TABLE 4
Clinical Properties of Current Food and Drug Administration–Approved Molecular Tracers Targeting Cell Surface Protein Transporters

Property	^{123}I-ioflupane	^{123}I-iobenguane and ^{131}I-iobenguane	^{68}Ga-PSMA11 and ^{18}F-piflufolastat
Indication	Striatal dopamine transporter imaging to assist in evaluation of adults with suspected Parkinsonian syndromes	^{123}I-iobenguane: detection of primary or metastatic pheochromocytoma or neuroblastoma; ^{131}I-iobenguane: treatment of adults and children older than 12 y with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma	PET of PSMA-positive lesions in prostate cancer patients who have suspected metastasis and are candidates for initial definitive therapy or who have suspected recurrence based on elevated serum prostate-specific antigen
Administered dose for adults	111–185 MBq (3–5 mCi)	^{123}I-iobenguane: 370 MBq (10 mCi); ^{131}I-iobenguane: 185–222 MBq (5–6 mCi) (dosimetric dose); 18,500 MBq (500 mCi) × 2 doses 90 d apart (therapeutic dose)	^{68}Ga-PSMA11: 111–259 MBq (3–7 mCi); ^{18}F-piflufolastat: 333 MBq (9 mCi) recommended; acceptable range, 8–296 to 370 MBq (10 mCi)
Injection route	Intravenous	Intravenous	Intravenous (bolus)
Injection-to-imaging time	3–6 h	24 ± 6 h	60 min
Normal biodistribution	Prominent comma-shaped striatal activity compared with surrounding brain tissue	Adrenals (not always visualized, but activity < liver), liver, heart (uptake inversely proportional to catecholamine levels), bowel (large intestine), salivary glands, lung, spleen, urinary bladder, and uterine/neck muscles	Kidneys, salivary glands, small intestine, tear glands, and spleen

result. By using a tracer that binds to the presynaptic dopamine transporters, one can obtain a quantitative measure and spatial distribution of these transporters and, hence, the dopamine secreting neurons (Table 4).

[123/131]I-Iobenguane (AdreView [GE Healthcare]/Azedra; Progenics Pharmaceuticals) (45)

[123/131]I-iobenguane, also known as MIBG, is structurally similar to the fight-or-flight hormone norepinephrine. Once secreted into the synapse between 2 neurons to facilitate neurotransmission, norepinephrine is taken back up into the presynaptic neurons through transporters called uptake 1. Uptake 1 is normally found in tissues but is overexpressed in certain neuroendocrine tumors, such as pheochromocytomas and neuroblastomas. Since MIBG resembles norepinephrine, it will be taken up in neuroendocrine tumor cells along with the neurotransporter in a higher amount. The radiolabeled MIBG is also a theranostic radiopharmaceutical; the same agent can be used for both diagnostic (^{123}I-MIBG) and therapeutic (^{131}I-MIBG) purposes (Table 4).

^{68}Ga-PSMA11 and ^{18}F-Piflufolastat (Pylarify; Lantheus) (46,47)

^{68}Ga-PSMA11 and ^{18}F-piflufolastat attach to the outer portion (extracellular domain) of the PSMA found in elevated levels (100- to 1,000-fold) on the surface of 95% of prostate cancer cells (48). PSMA is also normally seen at low levels in the kidneys, liver, tear glands, salivary glands, spleen, and nervous tissue. Once the radiotracer binds to the surface membrane protein, PSMA—along with the attached radiotracer—is transported into the cell, thus trapping the tracer within the cancer cell (Table 4) (49).

CONCLUSION

If past decades in nuclear medicine saw bold moves in physics and instrumentation, the future landscape is evolving to be the scintillating age of molecular and systems biology. The present and future growth of molecular imaging and therapy is based on using the intricate biologic and biochemical pathways of the human body. For the nuclear medicine technologist to appreciate the interactions of radiopharmaceuticals within the body and thus delineate the best information possible, a good understanding of the underlying mechanisms is required. This knowledge should be grounded in sound fundamentals of molecular processes in living systems, which will enable the technologist to integrate theory and processes into the realm of applied clinical practice. This ability will also engender a new generation of professionals who eagerly seek out cutting-edge knowledge and challenges that may elude the average health-care professional, leading the profession to the 21st century.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Whitford D. *Proteins: Structure and Function.* Wiley and Sons; 2005:528.
2. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. *Life Sci.* 1982;31:1133–1140.
3. Thalassemia major: molecular and clinical aspects. *Ann Intern Med.* 1979;91:883–897.
4. Merrick WC. Overview: mechanism of translation initiation in eukaryotes. *Enzyme.* 1990;44:7–16.
5. Schmitt E, Guillon JM, Meinnel T, Mechulam Y, Dardel F, Blanquet S. Molecular recognition governing the initiation of translation in *Escherichia coli*: a review. *Biochimie.* 1996;78:543–554.
6. Forbes J, Krishnamurthy K. Biochemistry, peptide. StatPearls website. https://www.statpearls.com/ArticleLibrary/viewarticle/26914. Updated September 1, 2021. Accessed April 7, 2022.
7. Ellis RJ. The general concept of molecular chaperones. *Philos Trans R Soc Lond B Biol Sci.* 1993;339:257–261.
8. Hartley RW. Barnase and barstar: two small proteins to fold and fit together. *Trends Biochem Sci.* 1989;14:450–454.
9. Al Mughram MH, Herrington NB, Catalano C, Kellogg GE. Systematized analysis of secondary structure dependence of key structural features of residues in soluble and membrane-bound proteins. *J Struct Biol X.* 2021;5:100055.
10. Perutz MF, Rossmann MG, Cullis AF, Muirhead H, Will G, North AC. Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by x-ray analysis. *Nature.* 1960;185:416–422.
11. Bringas M, Petruk AA, Estrin DA, Capece L, Marti MA. Tertiary and quaternary structural basis of oxygen affinity in human hemoglobin as revealed by multiscale simulations. *Sci Rep.* 2017;7:10926.
12. Davies DR, Padlan EA, Segal DM. Three-dimensional structure of immunoglobulins. *Annu Rev Biochem.* 1975;44:639–667.
13. Arrigo AP, Tanaka K, Goldberg AL, Welch WJ. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). *Nature.* 1988;331:192–194.
14. García-Morales V, Gonzalez-Acedo A, Melguizo-Rodriguez L, et al. Current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer's disease. *Biomedicines.* 2021;9:1910.
15. Filippi L, Chiaravalloti A, Bagni O, Schillaci O. ^{18}F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease. *Am J Nucl Med Mol Imaging.* 2018;8:268–281.
16. Wolters EE, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of [^{18}F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. *Eur J Nucl Med Mol Imaging.* 2021;48:2097–2109.
17. Lippincott-Schwartz J, Roberts TH, Hirschberg K. Secretory protein trafficking and organelle dynamics in living cells. *Annu Rev Cell Dev Biol.* 2000;16:557–589.
18. Nair A, Chauhan P, Saha B, Kubatzky KF. Conceptual evolution of cell signaling. *Int J Mol Sci.* 2019;20:3292.
19. Rizzieri D. Zevalin® (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? *Crit Rev Oncol Hematol.* 2016;105:5–17.
20. Leong SP. Detection of melanoma, breast cancer and head and neck squamous cell cancer sentinel lymph nodes by Tc-99m tilmanocept (Lymphoseek®). *Clin Exp Metastasis.* 2022;39:39–50.
21. Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands: the next generation for clinical practice. *Am J Nucl Med Mol Imaging.* 2018;8:311–331.
22. Katzenellenbogen JA. The quest for improving the management of breast cancer by functional imaging: the discovery and development of 16α-[^{18}F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review. *Nucl Med Biol.* 2021;92:24–37.
23. Bu M, Farrer MJ, Khoshbouei H. Dynamic control of the dopamine transporter in neurotransmission and homeostasis. *NPJ Parkinsons Dis.* 2021;7:22.
24. Tuma Santos CA, Wallace WD, Kim S, Vijayakumar V. Pitfalls and artifacts of ^{123}I-ioflupane SPECT in Parkinsonian syndromes: a quality improvement teaching tool. *J Nucl Med Technol.* 2021;49:114–119.
25. Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of ^{131}I-metaiodobenzylguanidine (MIBG) and ^{123}I-MIBG: clinical implications of the use of ^{123}I-MIBG. *Med Pediatr Oncol.* 1987;15:170–177.
26. Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. *Br J Radiol.* 2018;91:20180103.
27. Broer S. Amino acid transporters as targets for cancer therapy: why, where, when, and how. *Int J Mol Sci.* 2020;21:6156.

28. Gusman M, Aminsharifi JA, Peacock JG, Anderson SB, Clemenshaw MN, Banks KP. Review of ^{18}F-fluciclovine PET for detection of recurrent prostate cancer. *Radiographics.* 2019;39:822–841.

29. Schowen RL. How an enzyme surmounts the activation energy barrier. *Proc Natl Acad Sci USA.* 2003;100:11931–11932.

30. O'Keefe DS, Bacich DJ, Huang SS, Heston WDW. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. *J Nucl Med.* 2018;59:1007–1013.

31. Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. *J Exp Med.* 2018;215:159–175.

32. Kogai T, Ohashi E, Jacobs MS, et al. Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is mediated by the insulin growth factor-I/phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways. *J Clin Endocrinol Metab.* 2008;93: 1884–1892.

33. Furuya F, Shimura H, Suzuki H, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. *Endocrinology.* 2004;145:2865–2875.

34. Kogai T, Kanamoto Y, Li AI, et al. Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells. *Endocrinology.* 2005;146:3059–3069.

35. Dohán O, De la Vieja A, Carrasco N. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells. *Mol Endocrinol.* 2006;20:1121–1137.

36. Tanosaki S, Ikezoe T, Heaney A, et al. Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells. *Breast Cancer Res Treat.* 2003;79:335–345.

37. Chai W, Yin X, Ren L, et al. Sodium/iodide symporter gene transfection increases radionuclide uptake in human cisplatin-resistant lung cancer cells. *Clin Transl Oncol.* 2015;17:795–802.

38. Guerrieri F, Piconese S, Lacoste C, et al. The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells. *Cell Death Dis.* 2013;4:e807.

39. Ohashi E, Kogai T, Kagechika H, Brent GA. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. *Cancer Res.* 2009;69:3443–3450.

40. Liu Z, Xing M. Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells. *PLoS One.* 2012;7:e31729.

41. Kim HW, Kim JE, Hwang MH, et al. Enhancement of natural killer cell cytotoxicity by sodium/iodide symporter gene-mediated radioiodine pretreatment in breast cancer cells. *PLoS One.* 2013;8:e70194.

42. Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. *J Clin Endocrinol Metab.* 2006;91:69–78.

43. Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY, Brent GA. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. *J Endocrinol.* 2008;199:243–252.

44. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3′,5′-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. *Mol Endocrinol.* 2002;16:2266–2282.

45. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. *Biochem Biophys Res Commun.* 1997;240:832–838.

46. Bogazzi F, Bartalena L, Pinchera A, Martino E. Adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. *Thyroid.* 2002;12:1153–1154.

47. Romão R, Rubio IG, Tomimori EK, Camargo RY, Knobel M, Medeiros-Neto G. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism. *Thyroid.* 2009;19:945–951.

48. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. *Clin Cancer Res.* 1997;3:81–85.

49. Rajasekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. *Mol Biol Cell.* 2003;14:4835–4845.